These alterations were detected in 9 NSCLC samples (2 ALK rearrangements and 5 EGFR mutations, 1 BRAF mutation, and 1 G12C/KRAS mutation); 7 breast cancer samples (7 HER2 amplifications); 5 colon cancer samples (5 KRAS mutations); and 3 gastric cancer samples (2 MSI-high and 1 HER2 amplification). This evidence concerns the gene KRAS and breast cancer.